Amlodipine
Amlodipine is a calcium channel blocker taken by mouth. The US label read, for Norvasc, lists hypertension, to lower blood pressure, and coronary artery disease: chronic stable angina, confirmed or suspected vasospastic angina, and, in patients with recently documented coronary artery disease by angiography and without heart failure or an ejection fraction under 40%, reducing the risk of hospitalization for angina and of a coronary revascularization procedure.
Also called Norvasc · Amlodipine besylate
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 17767; UNII 864V2Q084H. The label names the substance as amlodipine besylate, so UNII 864V2Q084H is the UNII of the salt form and is a broad match. MeSH descriptor D017311 is Amlodipine. Class: Calcium Channel Blocker (FDA established pharmacologic class, RxClass). The label read is the NORVASC (amlodipine besylate), Viatris Specialty LLC label, effective 2023-02-15 in openFDA (application NDA019787). Other amlodipine labels in openFDA, from other sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 40 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 40
- Phase 3 or 4
- 30
- Recruiting
- 5
- Regulatory decisions
- 0
| Phase | Recruiting | Not yet recruiting | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|---|---|
| Phase 2 | 0 | 0 | 6 | 0 | 0 | 6 |
| Phase 2/3 | 1 | 0 | 1 | 0 | 2 | 4 |
| Phase 3 | 1 | 1 | 7 | 1 | 0 | 10 |
| Phase 4 | 3 | 1 | 11 | 1 | 4 | 20 |
| All phases | 5 | 2 | 25 | 2 | 6 | 40 |
Conditions these trials study
- Hypertension (high blood pressure)
- Chronic kidney disease (CKD)
- Coronary artery disease
- Dyslipidemia
- Ischemic stroke
- Stroke
- Adult congenital heart disease
- Angina pectoris
- Cerebral small vessel disease
- Coarctation of the aorta
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- Not reported
Classification codes
-
864V2Q084H
Claims and evidence
Context People for whom the US label of amlodipine (Norvasc) lists an indication: hypertension, chronic stable angina, vasospastic angina, documented coronary artery disease
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 4 inclusion criteria; exclusion criteria not stated
- Included
- Patients with hypertension
- Patients needing symptomatic treatment of chronic stable angina
- Patients with confirmed or suspected vasospastic angina
- Patients with recently documented coronary artery disease by angiography, without heart failure or an ejection fraction under 40%
- Excluded
- None stated
The US label of NORVASC (amlodipine besylate), in the Viatris Specialty LLC version dated 2023-02-15 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure; for the symptomatic treatment of chronic stable angina; for the treatment of confirmed or suspected vasospastic angina; and, in patients with recently documented coronary artery disease by angiography and without heart failure or an ejection fraction under 40%, to reduce the risk of hospitalization for angina and of a coronary revascularization procedure.
Applies to Recipient not specified People for whom the US label of amlodipine (Norvasc) lists an indication: hypertension, chronic stable angina, vasospastic angina, documented coronary artery disease
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0]
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2023-02-15
- Source state
- Current
- Version fingerprint
bf6df4ca425b576e31632a7221984d7eb04668134e654d030073338ba914819d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20230215.
- Retrieved
- Source effective date
- 2023-02-15
- Source state
- Current
- Version fingerprint
bf6df4ca425b576e31632a7221984d7eb04668134e654d030073338ba914819d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
AMLODIPINE BESYLATE
No label from the application holder was found in the openFDA label dataset for application NDA022026. This page does not show another labeler's label in its place.
AMTURNIDE
No label from the application holder was found in the openFDA label dataset for application NDA200045. This page does not show another labeler's label in its place.
AZOR
No label from the application holder was found in the openFDA label dataset for application NDA022100. This page does not show another labeler's label in its place.
CADUET
No label from the application holder was found in the openFDA label dataset for application NDA021540. This page does not show another labeler's label in its place.
CONSENSI
No label from the application holder was found in the openFDA label dataset for application NDA210045. This page does not show another labeler's label in its place.
EXFORGE
No label from the application holder was found in the openFDA label dataset for application NDA021990. This page does not show another labeler's label in its place.
EXFORGE HCT
No label from the application holder was found in the openFDA label dataset for application NDA022314. This page does not show another labeler's label in its place.
LOTREL
No label from the application holder was found in the openFDA label dataset for application NDA020364. This page does not show another labeler's label in its place.
NORLIQVA
No label from the application holder was found in the openFDA label dataset for application NDA214439. This page does not show another labeler's label in its place.
NORVASC
No label from the application holder was found in the openFDA label dataset for application NDA019787. This page does not show another labeler's label in its place.
PRESTALIA
No label from the application holder was found in the openFDA label dataset for application NDA205003. This page does not show another labeler's label in its place.
SDAMLO
No label from the application holder was found in the openFDA label dataset for application NDA219531. This page does not show another labeler's label in its place.
TEKAMLO
No label from the application holder was found in the openFDA label dataset for application NDA022545. This page does not show another labeler's label in its place.
TRIBENZOR
No label from the application holder was found in the openFDA label dataset for application NDA200175. This page does not show another labeler's label in its place.
TWYNSTA
No label from the application holder was found in the openFDA label dataset for application NDA022401. This page does not show another labeler's label in its place.
WIDAPLIK
No label from the application holder was found in the openFDA label dataset for application NDA219423. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
- Approval
NDA019787 - Approval
NDA020364 - Supplemental approval
NDA019787 - Supplemental approval
NDA019787 - Supplemental approval
NDA020364 - Supplemental approval
NDA019787 - Approval
NDA021540 - Supplemental approval
NDA019787 - Supplemental approval
NDA020364 - Approval
NDA021990 - Approval
NDA022100 - Approval
NDA022026 - Supplemental approval
NDA021990 - Approval
NDA022314 - Supplemental approval
NDA022100 - Approval
NDA022401 - Approval
NDA200175 - Approval
NDA022545 - Approval
NDA200045 - Approval
NDA205003 - Approval
NDA210045 - Approval
NDA214439 - Approval
NDA219423 - Approval
NDA219531
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists hypertension as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified People for whom the US label of amlodipine (Norvasc) lists an indication: hypertension, chronic stable angina, vasospastic angina, documented coronary artery disease
The US label of NORVASC (amlodipine besylate), in the Viatris Specialty LLC version dated 2023-02-15 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure; for the symptomatic treatment of chronic stable angina; for the treatment of confirmed or suspected vasospastic angina; and, in patients with recently documented coronary artery disease by angiography and without heart failure or an ejection fraction under 40%, to reduce the risk of hospitalization for angina and of a coronary revascularization procedure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists the symptomatic treatment of chronic stable angina as an indication: Stable angina
Applies to Recipient not specified People for whom the US label of amlodipine (Norvasc) lists an indication: hypertension, chronic stable angina, vasospastic angina, documented coronary artery disease
The US label of NORVASC (amlodipine besylate), in the Viatris Specialty LLC version dated 2023-02-15 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure; for the symptomatic treatment of chronic stable angina; for the treatment of confirmed or suspected vasospastic angina; and, in patients with recently documented coronary artery disease by angiography and without heart failure or an ejection fraction under 40%, to reduce the risk of hospitalization for angina and of a coronary revascularization procedure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists reducing the risk of hospitalization for angina and of coronary revascularization, in patients with angiographically documented coronary artery disease and without heart failure or an ejection fraction under 40%, as an indication: Coronary artery disease
Applies to Recipient not specified People for whom the US label of amlodipine (Norvasc) lists an indication: hypertension, chronic stable angina, vasospastic angina, documented coronary artery disease
The US label of NORVASC (amlodipine besylate), in the Viatris Specialty LLC version dated 2023-02-15 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure; for the symptomatic treatment of chronic stable angina; for the treatment of confirmed or suspected vasospastic angina; and, in patients with recently documented coronary artery disease by angiography and without heart failure or an ejection fraction under 40%, to reduce the risk of hospitalization for angina and of a coronary revascularization procedure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 16
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 4 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 40
Record details
- Record id
cardio:amlodipine- Content hash
de40f4c9407e82a5bc37f4afb4a95cc1b17df047422e5203f2f4ff6f7f9653a8